SCHEMBL3673443

SCHEMBL3673443

CCCCN1CCC(=O)Nc2cnc(Cl)nc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ MITF O75030 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ ALPG P10696 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ DDB1 Q16531 3/20 0.34
▸ CRBN Q96SW2 3/20 0.34
▸ NPC1 O15118 3/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ TSHR P16473 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ GAA P10253 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ RPS6KA3 P51812 2/20 0.32
▸ TYRO3 Q06418 1/20 0.32
▸ DYRK1B Q9Y463 1/20 0.32
▸ ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4089816 0.84 MTOR (0.37) ALDH1A1KDM4ELMNASMN1; SMN2DDB1
SCHEMBL3672260 0.77 SMN1; SMN2 (0.34) SMN1; SMN2RPS6KA3TYRO3DYRK1BABL1
SCHEMBL3668641 0.77 ALDH1A1 (0.35) ALDH1A1KDM4EMITFLMNAALPG
SCHEMBL31426004 0.72 CRBN (0.40) SMN1; SMN2CRBNRAB9AMEN1KMT2A
SCHEMBL3539972 0.71 PDE2A (0.33) GAAABL1BCR
SCHEMBL30878429 0.70 USP1 (0.44) —
SCHEMBL1203575 0.70 KDM4E (0.36) ALDH1A1KDM4ELMNAHPGDHSD17B10
SCHEMBL3666485 0.70 CRBN (0.33) SMN1; SMN2DDB1CRBNTYRO3DYRK1B
SCHEMBL30135929 0.70 KDM4E (0.36) ALDH1A1KDM4ELMNAHPGDHSD17B10
SCHEMBL3666481 0.70 KDM4E (0.36) ALDH1A1KDM4ELMNASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139892-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. Hoffmann-Roche AG (CH) 2010-01-06 — — EP disclosed
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 — — US disclosed
WO-2008113711-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-09-25 — — WO disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 ALDH1A1 1365/4885KDM4E 1150/4885MITF 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback